NovMetaHealth

For Your Healthy Life, NovMetaHealth

NovLC

Pipeline
NovLC
Program Target
Liver Cancer
Patient Numbers
0.85 Million
Development Stage
Research
NovMetaHealth researches and develops NovLC, a liver cancer medication of first-in-class new substance.

NovLC inhibits the proliferation of liver cancer cells (G1 arrest) by increasing Reactive Oxygen Species with a mechanism different from existing medications.
Therefore, unlike the existing medication, Tyrosine Kinase Inhibitor, the risk of developing resistance is relatively low.

Also, NovLC can be administered in combination with Tyrosine Kinase Inhibitor and additional effects of combined administration can be expected.
In fact, NovMetaHealth identified that when NovLC and Sorafenib (first-line therapy for liver cancer) were administered in combination, it overcomes the resistance of Sorafenib and reduces tumor.

NovLC Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Preclinical

Clinical phase 1/2a

02

Patent Application and Registration Status
Patents IP Protection
Liver cancer use patent (KR)
Application
2019
Patent expiration (expected) year
(2039)